NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis $5.37 +0.15 (+2.87%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.24▼$5.4250-Day Range$4.67▼$6.0452-Week Range$3.86▼$9.12Volume315,856 shsAverage Volume619,002 shsMarket Capitalization$649.16 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Exscientia alerts: Email Address Exscientia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside61.4% Upside$8.67 Price TargetShort InterestHealthy3.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.12) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector704th out of 936 stocksBiological Products, Except Diagnostic Industry118th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 1 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.06% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Exscientia has recently decreased by 2.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 3.0 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Exscientia this week, compared to 4 articles on an average week.Search Interest5 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is a decrease of -48% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to decrease in the coming year, from ($1.12) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -4.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesJuly 8, 2024 | investorplace.com3 Small-Cap Stocks With Explosive 2X Growth PotentialJune 25, 2024 | businesswire.comEXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law FirmJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 25, 2024 | prnewswire.comEXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming DeadlineJune 25, 2024 | prnewswire.comEXAI Today Is The Last Day that Investors can Lead Exscientia plc Fraud LawsuitJune 24, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c.June 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines - EXAIJune 24, 2024 | globenewswire.comEXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAIJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 24, 2024 | prnewswire.comEXAI DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action - EXAIJune 24, 2024 | businesswire.comEXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law FirmJune 22, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines – EXAIJune 21, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaJune 21, 2024 | globenewswire.comLowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 21, 2024 | globenewswire.comEXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law FirmJune 21, 2024 | prnewswire.comExscientia plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAIJune 20, 2024 | globenewswire.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)June 20, 2024 | globenewswire.comEXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAISee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/21/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+61.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-666.80% Pretax Margin-737.98% Return on Equity-34.59% Return on Assets-24.67% Debt Debt-to-Equity Ratio0.05 Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual Sales$25.60 million Price / Sales25.36 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.47Miscellaneous Outstanding Shares120,890,000Free Float101,062,000Market Cap$649.18 million OptionableOptionable Beta0.84 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $534.97kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandExecutive VP of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLSchrödingerNASDAQ:SDGRVericelNASDAQ:VCELCG OncologyNASDAQ:CGONIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 202,377 shares on 7/26/2024Ownership: 0.321%Baillie Gifford & Co.Sold 176,787 shares on 7/25/2024Ownership: 3.638%Platinum Investment Management Ltd.Sold 141,500 shares on 5/14/2024Ownership: 3.265%EntryPoint Capital LLCBought 5,784 shares on 5/14/2024Ownership: 0.026%Mitsubishi UFJ Trust & Banking CorpSold 25,530 shares on 5/10/2024Ownership: 0.125%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions How have EXAI shares performed this year? Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI stock has decreased by 16.2% and is now trading at $5.37. View the best growth stocks for 2024 here. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) issued its earnings results on Tuesday, May, 21st. The company reported ($0.21) EPS for the quarter. The firm had revenue of $6.70 million for the quarter. Exscientia had a negative net margin of 666.80% and a negative trailing twelve-month return on equity of 34.59%. When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. Who are Exscientia's major shareholders? Exscientia's top institutional investors include Baillie Gifford & Co. (3.64%) and Bank of New York Mellon Corp (0.32%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
